Selective internal radiotherapy (SIRT) using microsphere-bound radioactive drugs (Ytrium-90) administered directly through the arteries in liver cancer cases, is a modern interventional treatment that has become increasingly popular in recent years. It is a type of radiation therapy which focuses high doses of radiation on the tumor and minimize damage to healthy tissues around the liver. One advantage of radioembolization is that it can eliminate metastatic thrombosis. Therefore, it is also suitable for hepatocellular carcinomas with portal vein invasion (branches, sub-branches).
Y-90 is a radioisotope that is widely used in nuclear medicine for the treatment of cancer because it emits pure beta with a maximum energy of 2.27 MV with a half-life of 2.6 days and a penetration power to the liver tissue of 2.5 mm on average.
